Introduction: High quality research regarding treatment effectiveness, quality, and value is critical for improving the U.S. health care system. Recognition of this has led federal and state officials to better leverage existing data sources such as medical claims and survey data, but access must be balanced with privacy concerns.
Introduction
The United States health care delivery system is moving to a system that rewards quality, effectiveness, and value. Achieving these goals will require expanded research to inform clinical decision-making, promote evidence-based care at reasonable cost, and evaluate innovative system and payment designs. A bedrock requirement for success in these endeavors is the availability of real-world health data. 1 Recognition of this fact has led federal and state health officials to better utilize existing data sources including medical claims and survey data, and to leverage new data sources such as electronic medical records and patient registries. The federal government's Open Government Initiative has increased availability of government data and seeks to increase transparency, public participation, and collaboration around health care data sources. 2 A number of state governments have followed suit with the creation of "all-payer claims data sets" (APCDs). 3 The National Patient-Centered Clinical Research Network (PCORnet), 4 and The Innovation in Medical Evidence Development and Surveillance (IMEDS) program 5 that is offered by the Reagan-Udall Foundation and the United States Food and Drug Administration (FDA), are just two examples of other efforts underway that combine private and public sector data, creating new sources of information for health services research.
The most common data sets released by federal and state agencies constitute "public use files" (PUFs) that report aggregate health data. These files provide too few data elements or are not linkable to other files that are necessary to conduct the kind of inferential health services research needed to improve the effectiveness of our health care delivery system, however. For example, the Centers for Medicare and Medicaid Services (CMS) recently released a PUF with information on the prescription drugs that individual providers prescribed under the Medicare Part D Prescription Drug Program. 6 The PUF provides utilization data (total number of users and total number of prescriptions filled) and spending data (total drug costs) aggregated at the prescriber, drug name, and generic name levels. This provides an invaluable resource for describing patterns of prescription drug use and spending in the Medicare population at the national, state, or prescriber levels. But this file contains no individual patient-level data nor links to other data sources such as medical claims and thus cannot be used to assess drug adherence, evaluate drug safety, or compare outcomes for different drug treatments.
These types of analyses, including comparative effectiveness research and patient-centered outcomes research, require additional health information that is unavailable in PUFs. First, in order to assess treatment outcomes, data should be available at the individual level, rather than aggregated, to preserve the heterogeneity of individual characteristics, behaviors, and treatment impacts. Second, data sets should be longitudinal in order to distinguish temporal patterns of care, such as whether medication use is associated with delayed disease progression or whether patterns of care have an impact on hospitalization risk over time. Third, data on diagnoses, treatments, and outcomes must be dated-both to accurately describe the order of events (and tease out cause and effect) and to account for possible time-related confounding, such as seasonal variation in disease patterns. Fourth, fine-grained geographic detail regarding where patients live and are treated is essential to assessing contextual factors that affect health outcomes, such as residence in an urban versus rural neighborhood. Finally, observations for every data element must be linkable to specific individuals or providers included in the data set, in order to assess patient and provider characteristics that may have an impact on care. For many research questions, other variables and data links may be necessary. 1 
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A fundamental policy dilemma is the need to balance access while maintaining individual privacy and confidentiality. A myriad of federal laws apply to publicly funded health care data. For example, statutes such as the Freedom of Information Act and new initiatives such as Open Government seek to increase transparency, openness, and access to federal records. Other statutes, such as the Privacy Act, Health Insurance Portability and Accountability Act (HIPAA), and the Confidential Information Protection and Statistical Efficiency Act (CIPSEA) tend to restrict access to federal data (which include health data). The most specific of these is the Privacy Rule of HIPAA. 7 The Rule restricts access to health care data held by specified entities that function as health care providers or health plans (e.g., CMS, the Veterans Health Administration (VHA), and the National Institutes of Health (NIH) in some circumstances). Other entities not typically considered a covered entity (e.g., Agency for Healthcare Research and Quality), often comply with HIPAA. The Rule defines 18 elements of protected health information (PHI) that could be used to identify an individual (names, geographic identifiers below the state level except for the first three digits of a ZIP code, all elements of dates except year, telephone numbers, social security numbers, etc.). HIPAA permits disclosure without authorization when the information is used for approved uses (e.g., treatment, payment and health care operations, and for public health). When information is "de-identified" by one of two methods (formal determination by a qualified expert or removal of all 18 elements of PHI), the data is not considered PHI and is not subject to HIPAA restrictions. However, when disclosure of PHI is necessary, the researcher must obtain authorization from all research subjects, or if this is not feasible, a waiver of authorization from an institutional review board (IRB) or Privacy Board. The Rule also specifies limited data sets (LDS) as data sets with limited PHI (only dates and postal address information at or above the city name level) that can be released without authorization or documentation of a waiver when the data owner and researcher enter into a data use agreement (DUA).
Several federal agencies, particularly CMS, have developed LDS versions of their files and have also established the term "research identifiable files" (RIFs), for files containing PHI elements beyond what are found in their LDS files. In many cases, however, the sensitivity of the PHI found in LDS files is the same or greater than RIFs, and RIFs appear to match the definition of LDS found in the Rule. Inconsistencies also appear in the policies established by federal agencies to access LDS and RIF files. For example, requests for RIFs require more detailed DUAs and higher standards of data security than LDS, and certain LDS requests require IRB approval. Another difference between the file types is that LDS files are available in "shelf-ready" formats and cannot be individualized for specific patient cohorts or alternative sample sizes. In contrast, RIF samples can be customized and are subject to "minimum essential data" requirements that restrict sample cohorts and data elements to those deemed necessary to answer a specific research question.
Furthermore, some publicly funded RIFs are made available only to researchers in academic and nonprofit organizations and cannot be obtained by researchers associated with or funded by commercial entities. Other data sets can be accessed only by employees or contractors of the data owners. Even when data with PHI elements are released, data owners may limit the kinds of research that can be conducted (e.g., only studies with public health interest). Access may also be indirectly restricted by high data acquisition costs, complicated application procedures and licensing restrictions, delays in data turnaround, and costly data security safeguards.
This article catalogues and evaluates common access issues associated with the most widely sought, publicly funded health care databases. We reviewed 116 data sets currently available from federal agencies and state governments. We summarize our findings relating to 19 of these data sets, followed by discussion and recommendations for optimizing access to the kinds of health data necessary to speed our quest toward a high value health system while maintaining safeguards for individual privacy.
Methods
Our search strategy involved a landscape review of federal health agency websites, relevant published papers, gray literature, and personal contacts in order to generate a master list of individual-level health care data files available from federal and state agencies. Our initial search for federal data sets focused on data available from the following agencies or offices: (1) the CMS; (2) the Agency for Healthcare Research and Quality (AHRQ); (3) the FDA; (4) the Health Resources and Services Administration (HRSA); (5) the NIH; (6) the Substance Abuse and Mental Health Services Administration (SAMHSA); (7) the Centers for Disease Control and Prevention (CDC); (8) From this master list, we selected 19 data sets (9 federal and 10 state) for detailed review based on four criteria: (1) data were fully or partially publicly funded, (2) the unit of observation was at the individual rather than the population level, (3) data elements included service dates and geographic detail below the level of the state, and (4) data access policies for external researchers were fully developed. For federal agencies like CMS, which maintains multiple data sets meeting our inclusion criteria, we selected the data sets with the broadest policy relevance (e.g., Medicare and Medicaid data) in order to illustrate the data access policies of that agency. In cases where state APCDs made multiple versions of their files available with varying PHI levels, we restricted our review to versions meeting all four of our selection criteria.
Our analysis included the following points for each data set: name and web address or portal; a brief description of data files; type of file (LDS, RIF, etc.); identification of individual-level data (event dates, ages over 89, and lowest geocode of residence); restrictions on data access; data costs; required documentation and approvals; timeliness of data request approvals; data-storage, -release, and -access policies; and the most recent year of data available. We used the data owner's terminology when describing these elements even when they do not correspond to the exact definitions found in the HIPAA Privacy Rule. For example, for the type of file description, CMS refers to certain files as RIFs when in fact they qualify as LDS files under the rule. Similarly, for the required documentation and approvals, the terminology for DUAs is specific to requests for LDS files but CMS also calls the agreements with researchers to access and use RIFs as DUAs. Information was obtained by examining documentation on each agency's or organization's website and by contacting agency personnel to fill in data gaps. Data sets were determined to include PHI elements based on examination of data dictionaries, confirmation from the data owner, or evidence that the data set is available in a form linked to external
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files that include one or more PHI data elements (e.g., linkage with individual-level Medicare claims and enrollment files).
Results

Federal Data Sets
Our initial search identified 98 data sets from the federal agencies listed above. A majority of these data sets did not include individual-level data, event dates for medical services, or geographic detail below the level of the state; hence, they were excluded from further review. Table 1 As required in our selection criteria, each data set included individual-level health information sufficient to conduct high-quality, inferential health services research studies. Data elements include service dates, birth dates (except SEER-Medicare that includes birth month and year only), and date of death. Seven of the 9 include five-digit residential ZIP codes while 2 (the Medicare SAFs and the SEER-Medicare linked files) report residence at the county level. According to the HIPAA Privacy Rule's definitions, all of these files would be designated LDS. However, as noted above, some federal agencies, in particular CMS, designate these files as RIFs, reserving the LDS terminology for files with less sensitive PHI elements. Occasionally, these distinctions are not clear. For example, the MCBS (designated LDS) contains the same PHI data elements as CCW (RIF).
Most federal agencies permit access to users external to the agency; however, there is significant variation across agencies in access restrictions based on type of research, requestor, and funding source. Some agencies (e.g., CMS and the VHA) only make data available for research that advances the mission of their agencies, though it is unclear how that language is enforced. The VHA, which is the only federal agency in our review with electronic health record data available for research, further restricts access to those with Department of Veterans Affairs (VA) appointments although non-VA employees can obtain temporary VA appointments. While there are no explicitly stated restrictions on type of requestor for CCW and MAX files, CMS has not traditionally allowed use of RIFs for commercial purposes, including use by those deemed to be commercial entities.
On the other hand, other CMS data sets (e.g., Medicare SAFs and MCBS) have no such restrictions and are accessible by commercial entities. The SEER-Medicare linked files also have no explicit restrictions on type of requestor, but the NIH requires a letter explicitly indicating that researchers have freedom to publish all findings. The HRSMedicare linked data set is explicitly restricted to projects funded by a United States government grant, contract, or foundation. The request policies for the FDA's Mini-Sentinel distributed data network are unique among the federal databases we examined-in that access is restricted to the a Table 2 characterizes data costs, request processes, timelines for approval, data storage and management requirements, and access policies for each of the 9 federal data sets. There is considerable variation across and even within agencies in terms of how data fees are structured. Using the CCW as an example, the current cost for obtaining a random 5 percent sample of Medicare beneficiary records is approximately $35,000 per year of data at the high end. In contrast, the MCBS annual modules cost just $800.
To obtain LDS and RIFs, all data owners require a project summary, data management plan, and DUA. Four of the data sets additionally require a variable selection worksheet for particular variables (e.g., Part D data and functional assessment files). With the exception of the Medicare SAF files and the MCBS, all other data set requests are required to show additional evidence of internal review board (IRB) approval and to undergo privacy board review. While SEER-Medicare requires IRB approval, there is no privacy board review. The timelines and complexity of data request approvals also vary considerably. For instance, it typically takes 8 to 18 weeks to receive approval for the CCW and MAX files, whereas the Medicare SAF files and MCBS DUA applications are typically turned around in under a month.
Another issue of importance to researchers seeking federal data relates to data maintenance and security requirements. HIPAA Privacy, Security, and Breach Notification Rules dictate how entities receiving PHI must protect individual confidentiality through safeguards on transmission and storage of data, safeguards on data access given to investigators, and provisions for data destruction once the research has been completed. All data sets reviewed have rigorous policies on securing the research environment. Although HIPAA sets the same standards for all LDS files, CMS imposes stricter security measures for its RIFs (e.g., CCW and MAX files) compared to its LDS files (e.g., SAF and MCBS). Others (e.g., NHANES-Medicare linked files and VistA) are available only on-site or with remote 
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a $ denotes typically < $1000; $$ denotes typically >=$1000 and < $10,000; $$$ denotes typically > $10,000.
weeks. 
Data costs also vary widely across state APCDs (Table 4) . New Hampshire and Maryland do not charge a fee, whereas Oregon charges a fixed fee per file type per year of data to all requestors. Three APCDs (Colorado, Massachusetts, Maine) that permit access to external researchers use tiered pricing with higher fees for commercial entities and lower fees for academic and nonprofit institutions. Fees paid by nonprofits and academic institutions are typically one fourth to one half of the fees paid by other entities. Colorado is unique in that it has appropriated $500,000 to offset costs related to purchasing the APCD for academic institutions, state agencies, and nonprofits with revenue less than $5 million.
In order to request APCD data, Colorado, Massachusetts, Maryland, and Oregon require a project summary, data management plan, DUA, and variable selection sheet; however, procedures vary considerably. Oregon, Maryland, and Colorado (for its more PHI-sensitive file version) also require IRB or privacy review board approval. In terms of the recency of data available, APCDs from Maine, Maryland, and New Hampshire include close to realtime data, whereas the remainder lag by three to four years.
Discussion
Our review is the first to examine access and request policies for a broad cross section of publicly funded data sets available to researchers in the United States for analyses in areas such as comparative effectiveness research; patient-centered outcomes research; and access, cost, and quality of care research. We reached three important conclusions. First, there is significant heterogeneity in data access policies across the databases we reviewed, at both the federal and state levels. Second, access restrictions are not consistently related to the type or level of individual or protected health information (PHI) available in the data. Finally, even when data access is permitted to external researchers, there are various indirect barriers to access in the form of complex application procedures, fees, and data management requirements. We discuss each of these issues in further detail below.
We found significant variation in data access policies across federal agencies as well as for APCDs across state health agencies. In some cases, there was even variation in access policies across multiple data sets available from the same agency. This was particularly the case with CMS, wherein the variation stemmed from their designation of files based on the level of individual health information included. For example, despite the similar Medicare Part A and B claims data included in their Chronic Conditions Data Warehouse database and Standard Analytic Files, the one with geographic detail at the five-digit ZIP code level is designated as an RIF, whereas the one with county codes is classified as an LDS. In other cases, the LDS-RIF distinction is blurred. CMS's Medicare Current Beneficiary Survey contains the same PHI data elements as CMS's CCW files, but the former is designated an LDS and the latter is classified as an RIF. Although all the RIFs maintained by CMS should be classified as LDS files-based on the definition of LDS found in the HIPAA Privacy Rule-these distinctions in file types used by CMS are important, as they can have a major impact on the availability of individual-level data needed for high quality research, on whether or not certain types of researchers (particularly those funded by commercial entities) have access to the files, and also on the stringency of the data request approval process and data security requirements. In addition, policies from CMS have an impact on a broader array of data sets (e.g., the NIH's Health and Retirement Study or certain state APCDs) when those data sets are linked to Medicare data. They may also have an impact on new data infrastructure initiatives focused The purpose of the data request may be related to business operations or research that leads to the creation of products or tools that the requestor intends to sell. In addition to the standard process for approval of a research protocol under the existing research request process, innovator and entrepreneur requests require an additional level of review that will examine whether the use of the data could hurt beneficiaries or lead to fraud and abuse in CMS programs. This innovator and entrepreneur access policy is a significant shift in CMS's philosophy toward data access for commercial entities, and it will be interesting to observe how the policy evolves in the near future as requests are submitted and reviewed.
Some of the inconsistency in data access policies across agencies may stem from the fact that several federal laws have implications for privacy and data access; there is no single, coherent framework to govern data use decisions. 9 Some efforts to simplify this situation are underway, including proposed revisions to the federal Common Rule that seek to clarify and harmonize regulatory requirements and agency guidelines. 10 State and federal laws may also overlap or come into conflict, in which case the one with stricter privacy protections typically takes precedence. At the state level, differences in access policies may also reflect the range of intended uses of the data (e.g., for health department reports in Minnesota versus "to improve the health of Maine citizens" in Maine).
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Other groups have released a $ denotes typically < $1000; $$ denotes typically >=$1000 and < $10,000; $$$ denotes typically > $10,000.
reports offering guidance to states seeking to create or revise APCDs; this may lead to greater consistency in state APCD access policies. 12 We also observed numerous indirect hurdles to obtaining access to publicly funded databases that hinder use by all researchers. For instance, combining complex application procedures and high data user fees for the CCW (Medicare) and MAX (Medicaid) databases constrains access given the increasingly tight funding environment. Furthermore, the time from data request to approval and final data delivery may interfere with the ability to conduct and publish timely research. While LDS files available from CMS are cheaper with fewer complex applications and more timely delivery, these also raise issues for researchers. Specifically, some LDS do not contain complete utilization claims in one data set (e.g., Medicare SAF files exclude Medicare Part D data), thereby severely limiting the usefulness of these files. Others (e.g., the MCBS) contain full claims records but have insufficient sample size for health outcomes research. The differences in cost and time lag may be associated with the costs and resources required to generate minimum necessary data for specific research, the inability for some organizations to be remunerated for data services, or lack of workforce to effectively deidentify information using statistical methods. Given the rapid pace of medical innovation and quality improvement strategies in recent years, old data quickly become irrelevant and barriers that deter applicants or delay analysis have the potential to significantly curtail data utility and delay publication of important research findings.
Four study limitations warrant mention. First, while our selection of data sets was not exhaustive, we believe it to be representative of the larger universe of publicly funded United States health data sets that contain individual-level PHI variables and sufficient detail for conducting high quality research studies. Second, the information presented here was current as of November 2014, but readers should be forewarned that rules governing data accessibility are dynamic and subject to change. Third, although the accuracy and quality of secondary databases is critical to their utility in health services research, evaluating data integrity was outside the scope of our review. Fourth, while these policies are largely representative of data access associated with claims data, future policies for clinically rich data from electronic health records and mobile health are likely to refer to existing policies for precedence. Limited data and hurdles to the exchange of information are likely to dampen the promise and ability of electronic medical records and mobile health data to be shared across sites, providers, and systems to enable and incentivize high-quality care and reduce duplicative services.
Recommendations and Conclusions
Our analysis highlights the need for policymakers and data owners to carefully evaluate their data access and request policies and to remove unnecessary barriers to the utilization of these valuable resources. Several revisions to current policies may be useful. First, placing a greater emphasis on research quality and intent, rather than simply the investigator's affiliation, may create greater opportunities while maintaining the spirit of patient protection. There is little disagreement that certain commercial uses of these publicly funded data sets would be inappropriate (such as to aid marketing of a product or service), yet the notion of "commercial interest" has changed over time, given that provider groups, hospitals, and health plans could potentially use data to conduct research on factors that improve outcomes and performance, which can in turn influence both quality of care and profits. This thinking is reflected
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in a recent CMS policy revision, discussed earlier, which expands access to RIFs to the private sector. 9, 14 Shifting the focus to a user's ability to submit a research proposal that is of high quality (i.e., methodologically rigorous), with scientific justification for including specific data elements (e.g., more detailed geographic data that are needed to investigate a specific hypothesis), and that offers promising utility (e.g., the potential to improve program administration or the health of the covered population), may be more important than blanket inclusion or exclusion of researchers affiliated with an academic institution or commercial entity. For example, a pharmaceutical company may wish to use data for research designed to identify modifiable factors influencing medication adherence in order to strengthen patient support resources, or a hospital might wish to conduct research on highrisk patients and to discern key factors that reduce readmission rates. As with other areas of research, consistent policies (such as the International Committee of Medical Journal Editors guidelines that govern authorship in medical journals) and transparency (such as the requirement to post study information on clinicaltrials.gov) can increase public accountability, promote research rigor, and increase the generalizability of knowledge while addressing potential conflicts of interest. Data use policies might similarly include requirements to agree to agency stipulations regarding use and handling of data, to publicly post study protocols, and to publish or release all results within a specified period. Perceived financial conflict of interest could be addressed by permitting greater access through third parties that are not necessarily academic or nonprofit, as long as the involved parties meet certain agency criteria for independence.
Second, increasing the availability of researchidentifiable files may aid efforts to accelerate our understanding of precision medicine and to evaluate whether delivery system reform is having the intended impact on health care quality, effectiveness, and value. While LDS files may be sufficient for many questions, the inability to link to other files will leave many research questions unanswered. As information shifts from claims to clinically rich electronic health records, the ability to link across data sets will be increasingly important.
Third, remote access may ease the concerns of other stakeholders concerned with broader access to individual identifiable information. For example, resources such as the IMEDS Data Lab and CMS Virtual Research Data Center enable remote access to RIFs in a secure environment, reduce the need for one-off storage by individual researchers, and allow individual-level analysis while limiting the ability to download study results to the aggregate (rather than individual) level.
Finally, alleviating direct access barriers may reduce indirect barriers as well. For example, a tiered pricing approach for data user fees-whereby commercial entities with greater resources are charged higher fees that help offset lower fees collected from academic and nonprofit organizations-could enable more investigators to explore important research questions. Expanding access could also have the potential to reduce time lag barriers by generating revenue to support increased staffing and more timely processing. This is the approach taken by the United Kingdom's Clinical Practice Research Datalink (CPRD) GOLD, a publicly funded, primary-care research database of computerized medical records from across the United Kingdom.
Greater consistency and simplicity in agency policies have the potential to increase access to, and thereby the utility of, a wide spectrum of publicly funded health care data sets. Further, greater consistency regarding the treatment of PHI, including reconciliation of federal laws, is needed. Finally, a framework that focuses more on user qualifications and intent across stakeholder groups, as opposed to simply user affiliation, would enable research that evaluates our current progress and moves us closer to our goals for a health care system that rewards quality, efficiency, effectiveness, and value.
